Clinical trial
Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease
NCT00088673 · Bellus Health Inc. - a GSK company, Industry · Unknown status
Key facts
| NCT number | NCT00088673 |
|---|---|
| Title | Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease |
| Official title | A Phase III Study of the Efficacy and Safety of 3APS in Patients With Mild to Moderate Alzheimer's Disease |
| Lead sponsor | Bellus Health Inc. - a GSK company, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | 3APS |
| Enrollment | 950 |
| Start date | Jun 1, 2004 |
| First posted | Aug 3, 2004 |
| Last update posted | Feb 28, 2007 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: